U.S. Gains COVID-19 Drug Monopoly for Gilead’s 31,900% Markup
The U.S. government and Gilead have colluded in the fleecing of taxpayers by agreeing a huge 31,900% markeup for Covid-19 drug remdesivir.
Simon Chandler July 1, 2020
The U.S. government and Gilead have colluded in the fleecing of taxpayers by agreeing a huge 31,900% markeup for Covid-19 drug remdesivir.
Gilead Sciences stock is rallying today. But it’s safe to say the reason why – remdesivir’s four-figure price tag – is going to sicken you.
U.S. stock markets are rallying after an inconclusive study on Gilead’s remdesivir. The flimsy trial didn’t even have a control group.
Gilead was quick to downplay a leaked WHO document showing its coronavirus treatment failed in a Chinese trial. But the numbers don’t add up.
The Dow Jones swung wildly after coronavirus drug remdesivir failed its first trial and ING reported a harrowing unemployment stat.
The Dow Jones soared into the closing bell, even as its biggest stocks – UnitedHealth and Apple – dove back into decline. Here’s why.
Remdesivir, an antiviral drug developed by Gilead Sciences to treat Ebola, has shown anecdotal evidence of treating COVID-19.